All In Biotech

NDA 212125 · Teva Pharms USA INC

Micafungin

Micafungin Sodium · Intravenous

Discontinued

Last checked: Nov 20, 2026Latest source record: Jul 30, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Jul 30, 2021

Approved uses

1

Original approval plus efficacy supplements

Registered trials

58

16 Phase 3, 0 recruiting

FAERS reports

6,576

6,281 serious, 2,438 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 30, 2021 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
2 products under this application
  • MICAFUNGIN · MICAFUNGIN SODIUM EQ 50MG BASE/VIAL · POWDER, INTRAVENOUS · Discontinued
  • MICAFUNGIN · MICAFUNGIN SODIUM EQ 100MG BASE/VIAL · POWDER, INTRAVENOUS · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Micafungin" as an intervention, any sponsor and status, largest first.

All 58 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,105
  • off label use691
  • pyrexia487
  • febrile neutropenia435
  • product use in unapproved indication320
  • pneumonia313
  • sepsis308
  • multiple organ dysfunction syndrome281
  • diarrhoea271
  • neutropenia264
  • acute kidney injury254
  • respiratory failure244

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200411
200518
200630
200755
200849
200948
201085
2011172
2012200
2013143
2014175
2015315
2016259
2017353
2018460
2019481
2020459
2021539
2022529
2023568
2024577
2025605
2026445

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Micafungin (Micafungin Sodium)

2024 spending

$6.6M

Beneficiaries

4,453

16,662 claims

Per beneficiary

$1,483

$13.44 per unit

View as table
YearSpending
2020$2,551,847
2021$7,231,408
2022$8,180,528
2023$10,153,033
2024$6,603,051

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 130 on PubMed

Sponsor: Teva

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.